Axitinib

證據等級: L5

預測適應症: 10 個

Axitinib: From Renal Cell Carcinoma to Xp11.2 Translocation/TFE3 Fusion-Associated Renal Cell Carcinoma

One-Sentence Summary

Axitinib is a selective VEGFR1/2/3 tyrosine kinase inhibitor already approved worldwide (as Inlyta) for advanced/metastatic renal cell carcinoma. The TxGNN model predicts it may also be effective for renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions, a rare, genetically distinct RCC subtype seen mainly in children and young adults, with 1 clinical trial currently supporting this direction and no published literature specific to this subtype yet.

Quick Overview

Item	Content
Original Indication	Advanced/metastatic Renal Cell Carcinoma (globally approved as Inlyta; per evidence pack, this is axitinib's existing core indication, not a new use)
Predicted New Indication	Renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions
TxGNN Prediction Score	99.90%
Evidence Level	L2
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for axitinib is not available in this evidence pack (original_moa: Data Gap). Based on information embedded in the repurposing rationale, axitinib is a highly selective, potent inhibitor of VEGFR1, VEGFR2, and VEGFR3, and it is already the approved standard of care for advanced/metastatic renal cell carcinoma — this appears in the evidence pack itself as the drug's existing core indication, not a repurposing candidate.

Xp11.2 translocation/TFE3 gene fusion RCC is a genetically and histologically distinct RCC subtype, most common in children, adolescents, and young adults. Despite its distinct molecular driver (TFE3 fusion), tumor biology in this subtype still shows VEGF/mTOR pathway activation, providing a plausible mechanistic rationale for extrapolating axitinib's antiangiogenic activity from classic clear-cell RCC to this subtype. However, subtype-specific efficacy evidence remains sparse — the only supporting trial enrolls a broad translocation/TFE3-RCC population "across all age groups" rather than confirming activity specifically in the Xp11.2 fusion subtype.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03595124	Phase 2	Active, not recruiting	15	Randomized trial of axitinib/nivolumab combination vs. single-agent nivolumab in TFE/translocation RCC across all age groups; small sample, no subtype-specific stratification for Xp11.2 fusion reported.

Literature Evidence

Currently no related literature available.

Norway Market Information

Axitinib is currently not marketed in Norway (0 authorizations recorded). No dosage forms, product names, or approved indication texts are available for this market.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (VEGFR1/2/3 tyrosine kinase inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The only supporting trial (NCT03595124) is a small (n=15) Phase 2 study covering a broad translocation/TFE3-RCC population rather than confirming activity specifically in Xp11.2 fusion-associated RCC, and no literature currently supports this specific indication. Combined with the drug's unmarketed status in Norway and blocking gaps in TFDA/local safety labeling, evidence is insufficient to advance beyond a research question at this stage.

To proceed, the following is needed:

TFDA/Norwegian package insert data (warnings, contraindications) — currently a Blocking data gap (DG001)
Detailed mechanism of action documentation via DrugBank API (DG002)
Mature, subtype-stratified results from NCT03595124 confirming efficacy specifically in Xp11.2/TFE3 fusion RCC
Assessment of the regulatory pathway for Norway market entry, given axitinib currently holds zero local authorizations
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.